Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gem-associated protein 7 (GEMIN7) is a core component of the **survival of motor neuron (SMN) complex**, which is essential for the assembly of **spliceosomal small nuclear ribonucleoproteins (snRNPs)**, the main building blocks of the spliceosome that catalyzes pre-mRNA splicing in eukaryotic cells[1][2][4][6][7][8]. GEMIN7 localizes to the nucleoplasm, cytoplasm, and distinctive nuclear bodies known as "gems" (Gemini of Cajal bodies)[1][5][8]. It forms a heterodimer with Gemin6, adopting an **Sm protein-like fold** and facilitating the organization and assembly of Sm protein rings on snRNAs[3]. GEMIN7 interacts directly with SMN, Gemin6, and several Sm proteins, playing a critical role in snRNP biogenesis. Dysfunction in components of the SMN complex, including GEMIN7, is implicated in **spinal muscular atrophy** and other neurodegenerative diseases[5]. No drugs or direct mechanisms of action targeting GEMIN7 are currently described, and it is not considered a therapeutic target[1][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gem-associated protein 7 (GEMIN7).